At the first follow-up video consultation, 90% of the patients reported an improvement in their general condition. Cumulatively over the entire observation period of 6 months, 97 (99%) patients reported an improvement in their general condition at one or more follow-up interviews, as shown in Figure 4b.
Over the six follow-up consultations, good therapy tolerance was reported in 279 (91%) out of the cumulative 307 available answers as shown in Figure 4c. Reports regarding side effects were available cumulatively in 335 interviews over the six follow-up consultations. No serious adverse events were reported, e.g., psychosis, heavy tachycardia, breathing problems, or deficits in vital activities such as sleep and sexuality. Mild side effects were reported infrequently as summarized in Table 2. These included dryness of the mucous tissue (5.4%), fatigue (4.8%), and increased appetite (2.7%). The rate of all reported mild side effects was 12.9% with an error margin of 3.6%. There were single reports of rare adverse events such as dizziness, intoxication, restlessness, and nausea. Also, there were single reports of unusual experiences such as unpleasant smell of the medical cannabis, shortness of memory, stress, strong sedating effects.